[Skip to Content]
[Skip to Content Landing]
Citations 0
Editor's Correspondence
December 9/23, 2002

Risk of Myocardial Infarction Associated With Selective COX-2 Inhibitors: Questions Remain

Author Affiliations

Copyright 2002 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2002

Arch Intern Med. 2002;162(22):2639. doi:

The 3 case-control studies by Drs Rahme, Solomon, Watson, and their colleagues1-3 published recently in the ARCHIVES suggest that the main reason for an increased risk of MI found for rofecoxib when compared with naproxen in the Vioxx Gastrointestinal Outcomes Research (VIGOR) trial4 may be a cardioprotective effect of naproxen. We have 2 concerns with this interpretation.

First Page Preview View Large
First page PDF preview
First page PDF preview